miR-210 Jung and colleagues [87] examined the plasma miR-210 expression level in patients with HER2+ breast cancer before (that is, baseline expression) and after neoadjuvant chemotherapy (NCT) that included trastuzumab. Here, ERBB2 is linked to breast carcinoma.